Mounjaro sales dip amid price war as semaglutide generics gain groundMounjaro, the star pharmaceutical from Eli Lilly, is experiencing a downturn in sales across India. This slump can be attributed to competi...
10 Apr, 2026, 09.22 AM IST
Novo Nordisk’s weight-loss drug patent loss sparks a ‘gold rush’ for generic drugmakersIndia's weight-loss drug market is seeing a major shift. Generic versions of Novo Nordisk's semaglutide are now available at lower prices. ...
09 Apr, 2026, 02.52 PM IST
India's 'Mounjaro brides': Weight-loss injections become part of pre-wedding preparationWith wedding season in full swing, Indian health clinics are rolling out specialized weight-loss packages that include popular drugs such a...
03 Apr, 2026, 02.24 PM IST
Rs 450 to Rs 4,200: Drugmakers rush in to win the business of losing weightNovo Nordisk's weight-loss drug patents have expired in India. Several generic companies have launched their versions, increasing competiti...
24 Mar, 2026, 04.15 PM IST
Natco, Eris Life to launch slimming shots in both Vial and Pen formatsNatco Pharma and Eris Lifesciences are launching generic semaglutide weight-loss injections. The companies are introducing both vial and pe...
21 Mar, 2026, 09.35 AM IST
Eli Lilly sticks to premium pricing for its innovator drug ahead of generics waveEli Lilly remains optimistic about strong demand for its weight-loss and anti-diabetes injectable, tirzepatide (sold as Mounjaro), despite ...
02 Mar, 2026, 12.09 AM IST
What’s powering Mounjaro’s rise to the top of Indian drug marketMounjaro has made a splash in Indian healthcare, emerging as the go-to solution for both diabetes management and weight loss. This remarkab...
03 Nov, 2025, 10.47 PM IST
Cipla to sell Lilly's weight-loss drug in IndiaEli Lilly and Cipla have joined forces. Cipla will now market Lilly's popular weight-loss drug in India. The medication will be sold under ...
24 Oct, 2025, 02.51 PM IST
Lilly, Cipla ink distribution pact for weight loss, type 2 diabetes treatment drug YurpeakIn an exciting collaboration, Cipla and Eli Lilly have unveiled Yurpeak, a groundbreaking diabetes and weight management medication, now av...
23 Oct, 2025, 08.32 PM IST
Eli Lilly's obesity drug Mounjaro's India sales hit a sweet spot within six months of launchLilly's Mounjaro has rapidly become the second-highest selling drug in India's pharmaceutical market, achieving ₹233 crore in sales within ...
08 Oct, 2025, 06.07 AM IST
Eli Lilly launches Mounjaro KwikPen for diabetes, obesity treatment in IndiaEli Lilly has launched Mounjaro in KwikPen, a prefilled pen for weekly administration, in India to treat type 2 diabetes and obesity. Price...
13 Aug, 2025, 07.33 PM IST
Weight-loss drug Mounjaro crosses Rs 100 crore sales in 4 monthsThe drug clocked Rs 47-crore sales in July, double its June figure, according to data from prescriptions tracker PharmaTrac. If this month-...
08 Aug, 2025, 03.21 PM IST
Eli Lilly to roll out diabetes medicine in prefilled penEli Lilly will soon launch Mounjaro KwikPen in India. This follows regulatory approval for the diabetes and obesity drug. The KwikPen offer...
08 Jul, 2025, 01.11 PM IST
Eli Lilly to launch Mounjaro KwikPen for type 2 diabetes in IndiaEli Lilly is set to launch Mounjaro in KwikPen, a user-friendly, prefilled pen for weekly administration, in India, following regulatory ap...
08 Jul, 2025, 01.10 PM IST
Mounjaro crosses Rs 50 cr in India in 90 days as Wegovy joins frayMounjaro, Eli Lilly's weight-loss drug, witnessed a massive sales jump in India since March. Sales reached ₹26 crore in June. Wegovy from N...
08 Jul, 2025, 01.10 PM IST
Lilly to launch Mounjaro pen in India to compete with Novo's WegovyEli Lilly announced that India’s drug regulator has approved its Mounjaro KwikPen, a pre-filled injector pen for weight loss and diabetes t...
26 Jun, 2025, 01.15 PM IST
Waiting for a wonder drug? The weight just got longerEli Lilly awaits India's approval to sell Tirzepatide, marketed as Mounjaro and Zepbound in the US. CEO David Ricks plans to launch the dru...
04 Jul, 2024, 05.30 AM IST